Brain Perfusion & Oxygenation in Parkinson's Disease With NOH
Status:
Unknown status
Trial end date:
2020-08-01
Target enrollment:
Participant gender:
Summary
This is a double blind placebo controlled trial in Parkinson's disease (PD) patients with
neurogenic orthostatic hypotension (NOH). Investigators hypothesize that the study drug
(droxidopa) may improve cerebral perfusion more robustly than systemic BP, possibly by direct
action within the CNS vasculature. This study is designed to determine if droxidopa improves
cerebral perfusion measures in PD patients with NOH, in addition to peripheral BP measures
and subjective responses.